Stock Events

H. Lundbeck AS 

kr34.3
13
+kr0+0% Today

Statistics

Day High
34.3
Day Low
34.3
52W High
37.98
52W Low
27.55
Volume
36
Avg. Volume
1,415
Mkt Cap
-
P/E Ratio
-
Dividend Yield
2.07%
Dividend
0.71

Upcoming

Dividends

2.07%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
20.69%

Earnings

8NovConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
0.7
2.02
3.35
4.67
Expected EPS
0.72
Actual EPS
0.96

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0ABR.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.
Show more...
CEO
Dr. Deborah Dunsire M.D.
Employees
5452
Country
Denmark
ISIN
DK0061804697
WKN
000A3DMBU

Listings